Reflecting on Advances in NSCLC Treatment Over the Past 10 Years

Video Library —May 5, 2021
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T)
Thoracic Oncology Nurse Navigator
Community Healthcare System
Munster, Indiana
Cathy Simmons, RN, BSN, ONN-CG(T)
Thoracic Oncology Navigator
Sarah Cannon Cancer Institute
Plano, Texas
Lauren Welch, MSN, NP-C, AOCNP
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Kammi Fox-Kay, Cathy Simmons, and Lauren Welch describe their perspectives on advances in NSCLC treatment over the past decade, focusing on the development of targeted agents and the discovery of new molecular targets for therapy, as well as the expanding use of immunotherapy as first-line therapy for NSCLC. They describe this as a “thrilling time” in NSCLC treatment where they can reassure their patients that they will be able to live longer with their disease, even at stage III or IV.
Related Articles
Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
Interview with the Innovators – December 2021
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.
The Importance of Accurate Staging in Prostate Cancer
Neal Shore, MD, FACS
|
Web Exclusives
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Use of PYLARIFY® in Specific Patient Groups
Neal Shore, MD, FACS
|
Web Exclusives
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Last modified: May 21, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code